Scopolamine and ketamine: Evidence of convergence?

Biological Psychiatry

Volumn 74, Issue 10, 2013, Pages 712-713

  Monteggia, Lisa M ^a   Kavalali, Ege T ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; GLUTAMIC ACID; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MONOAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; PHOSPHOLIPASE C; SCOPOLAMINE; TELENZEPINE;

ANTIDEPRESSANT ACTIVITY; DEPRESSION; DRUG EFFICACY; DRUG HALF LIFE; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; LONG TERM POTENTIATION; LOW DRUG DOSE; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; NOTE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS; THERAPY EFFECT; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; MALE; STRESS, PSYCHOLOGICAL;

EID: 84886658663     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.08.011     Document Type: Note

References (10)

1. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
2. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
3. M.L. Furey, and W.C. Drevets Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial Arch Gen Psychiatry 63 2006 1121 1129
4. A.E. Autry, M. Adachi, E. Nosyreva, E.S. Na, M.F. Los, and P.F. Cheng NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
5. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, and M. Iwata mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
6. M. Aan Het Rot, C.A. Zarate Jr, D.S. Charney, and S.J. Mathew Ketamine for depression: Where do we go from here? Biol Psychiatry 72 2012 537 547
7. E.M. Parise, L.F. Alcantara, B.L. Warren, K.N. Wright, R. Hadad, and O.K. Sial Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats Biol Psychiatry 74 2013 750 759
8. B. Voleti, A. Navarria, R-J. Liu, M. Banasr, N. Li, and R. Terwilliger Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses Biol Psychiatry 74 2013 742 749
9. E. Nosyreva, K. Szabla, A.E. Autry, A.G. Ryazanov, L.M. Monteggia, and E.T. Kavalali Acute suppression of spontaneous neurotransmission drives synaptic potentiation J Neurosci 33 2013 6990 7002
10. E.T. Kavalali, and L.M. Monteggia Synaptic mechanisms underlying rapid antidepressant action of ketamine Am J Psychiatry 169 2012 1150 1156